Merck and The Michael J. Fox Foundation Offer Service to Advance Parkinson’s research
Merck, a leading science and technology company, and The Michael J. Fox Foundation for Parkinson's Research (MJFF), are advancing research aimed at slowing progression of Parkinson’s disease (PD). Through funding from MJFF’s “Biomarkers to Support Therapeutic Trials Program”, Merck's SMCxPRO® immunoassay technology has been used to help detect low levels of a biomarker associated with cell dysfunction in patients. Now, the service is available to the scientific community through support from the MJFF. This will make it possible to track the response of different therapeutic options to disease progression.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240618168747/en/
(Photo: Business Wire)
“Using the SMCxPRO® immunoassay technology to assess cell dysfunction represents a significant step forward in developing new treatment options for people fighting PD,” said Jean-Charles Wirth, Head of Science & Lab Solutions, Life Science business sector of Merck. “We’re proud to offer our service through support from The Michael J. Fox Foundation to make this research possible. Our goal is to empower breakthroughs in neuroscience research tools and other technologies that impact life and health with science.”
The research is focused on the biomarker pS65 ubiquitin (pS65-Ub). PD is a neurodegenerative disease that predominantly affects certain nerve cells in a specific area of the brain. By the time motor symptoms become visible, 60% to 80% of these cells have already been lost or impaired. Before that, affected cells stop functioning properly, which ultimately leads to their death. One readout of dysfunction in these cells is pS65-Ub. Extremely sensitive test methods are required to detect it. Using the SMCxPRO® immunoassay platform, used to quantify levels of a specific target within a sample, scientists can now detect small concentrations of pS65-Ub. This helps, for the first time, to track the response of different therapeutic options on disease progression.
“Ultrasensitive assays allow us to research multiple biomarkers we know play a role in disease progression. These would be valuable to diagnose and stratify patients and for future therapeutic development. Current known therapies for PD can treat symptoms but do not slow or halt disease progression. We are hopeful this collaboration will contribute to improved quality of life for patients,” said Nicole Polinski, PhD, director of research resources at MJFF.
Currently, PD impacts around 10 million people worldwide. Its prevalence has doubled in the past 25 years, making it the fastest-growing neurological condition in the world. The number of people with the disease is expected to further grow to 20 million by the year 2050. Merck’s contribution to Parkinson research has been recognized by CiteAb Awards, based on being the company with the most citations related to Parkinson’s research in 2023.
About Merck
Merck, a leading science and technology company, operates across life science, healthcare and electronics. Around 63,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2023, Merck generated sales of € 21 billion in 65 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.
All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240618168747/en/
Contacts
Media Relations
rachel.bloom-baglin@merckgroup.com
Phone: +49 (6151) 72-44461
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BST Global Launches AI + Data Impact Survey for the AEC Industry12.11.2024 16:41:00 CET | Press Release
BST Global, the leading provider of AI-powered project intelligence™ solutions for the AEC industry, has launched its groundbreaking AI + Data Survey globally. Seeking insights from technology and data leaders of architecture, engineering and environmental consultancies around the world, the survey will be available until 11:59 p.m. ET, December 13, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241112980057/en/ BST Global, the leading provider of AI-powered project intelligence™ solutions for the AEC industry, has launched its groundbreaking AI + Data Survey globally. Seeking insights from technology and data leaders of architecture, engineering and environmental consultancies around the world, the survey will be available until 11:59 p.m. ET, December 13, 2024. (Graphic: BST Global) BST Global partnered with BST Global’s AI + Data Consortium and the American Council of Engineering Companies' (ACEC) Technology Committ
Medidata and Bioforum Bolster Decade-Long Relationship to Advance Clinical Data and Biometric Solutions for Clinical Trials12.11.2024 16:40:00 CET | Press Release
Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced a new enterprise agreement with Bioforum, a biometrics CRO that serves clinical trial sponsors worldwide. Building on more than a decade of collaboration, the expanded partnership provides Bioforum’s biotech customers with broader access to Medidata’s AI-powered technology, enabling a more agile clinical development experience. In addition to Medidata solutions such as Medidata Rave EDC and Medidata Rave RTSM, which Bioforum has leveraged to deliver 60 studies across a range of therapeutic areas, the CRO is adding Medidata Clinical Data Studio and Medidata eConsent to streamline data flow, maintain data integrity, and ensure compliance. “With our team of experts, industry-leading biometric services, and proprietary technology, Bioforum empowers sponsors to seamlessly manage their clinical data in one place and ensure it’s secure, accurate, and ready for an
ATRC’s VentureOne Launches QuantumGate to Secure Data for the Quantum Era at CyberQ12.11.2024 16:37:00 CET | Press Release
The Advanced Technology Research Council’s commercialization arm, VentureOne, has launched QuantumGate, a new venture that offers a suite of advanced data security products to protect organizations’ data assets in the quantum era, at CyberQ in Abu Dhabi today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241112430830/en/ ATRC’s VentureOne Launches QuantumGate to Secure Data for the Quantum Era at CyberQ (Photo: AETOSWire) H.E. Faisal Al Bannai, the Secretary General of ATRC, said, “The quantum era isn’t a distant threat—it is here. The launch of QuantumGate is a pivotal step in safeguarding invaluable data assets against ever-increasing cybersecurity threats. QuantumGate’s sovereign solutions will ensure our country’s and our organizations’ sensitive information stays safe.” “Cryptographic algorithms are used by virtually all organizations to encrypt and protect data,” said Dr. Najwa Aaraj, the CEO of the Technology Innova
DEWA Reports Highest Top Line Results in History With a Record First 9-Month Revenue of AED 23.5 Billion and EBITDA of AED 11.8 Billion12.11.2024 16:13:00 CET | Press Release
Dubai Electricity and Water Authority PJSC (ISIN: AED001801011) (Symbol: DEWA), the Emirate of Dubai’s exclusive electricity and water services provider, which is listed on the Dubai Financial Market (DFM), today reported its first 9-month consolidated financial results for 2024, recording cumulative revenue of AED 23.5 billion, EBITDA of AED 11.8 billion, and net profit after tax of AED 5.5 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241112471782/en/ HE Saeed Mohammed Al Tayer, MD & CEO of DEWA. (Photo: AETOSWire) “We are committed to excellence and sustainable growth, guided by the visionary leadership of His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the directives of His Highness Sheikh Hamdan bin Mohammed bin Rashid Al Maktoum, Crown Prince of Dubai, Deputy Prime Minister and Minister of Defence, and His Highness Sheikh Maktoum bin Moh
Syteca Introduces Account Discovery Feature to Strengthen Privileged Access Management12.11.2024 15:27:00 CET | Press Release
Syteca, Inc., a leading provider of cybersecurity solutions, today announced the launch of Account Discovery, a new feature within its Privileged Access Management (PAM) solution. This enhancement enables organizations to automatically detect and manage privileged accounts across their IT infrastructure, significantly reducing security risks associated with unmanaged access credentials. The new Account Discovery feature addresses the critical challenge of "ghost accounts" – privileged credentials that remain active after employee departures, contractor project completions, or system upgrades. These overlooked accounts often create security vulnerabilities that can be exploited by cybercriminals for lateral movement, data theft, and privilege escalation. With Account Discovery, we're giving our customers the tools they need to maintain complete visibility and control over all privileged access points in their network. Key benefits of Syteca's account discovery feature: Automated Discove
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom